Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Inhibitory Effects of AE0047, a New Dihydropyridine Ca2+ Channel Blocker, on Renal Nerve Stimulation-Induced Renal Actions in Anesthetized Dogs

Tomoyuki Yamasaki, Masaji Ohmagari, Isao Tamai, Kazutaka Hayashi and Yasuo Matsumura
Journal of Pharmacology and Experimental Therapeutics June 2000, 293 (3) 1040-1047;
Tomoyuki Yamasaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaji Ohmagari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isao Tamai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazutaka Hayashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuo Matsumura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The effects of AE0047, a newly developed dihydropyridine Ca2+ channel blocker, and nicardipine on changes in the renal function and norepinephrine (NE) overflow induced by renal nerve stimulation (RNS) were examined in anesthetized dogs. RNS at a low frequency (0.5–2.0 Hz) caused significant decreases in the urine flow, urinary excretion of sodium, and fractional excretion of sodium, while also inducing increases in the NE secretion rate (NESR), without affecting the renal hemodynamics. RNS at a high frequency (2.5–5.0 Hz), which diminishes the renal blood flow, glomerular filtration rate, and filtrate fraction, elicited more potent decreases in urine formation and increases in NESR than those seen for the low-frequency RNS. When AE0047 (10 and 50 ng/kg/min) was administered intrarenally, increases in the basal renal blood flow and urine formation were observed. During AE0047 (50 ng/kg/min) infusion, low-frequency RNS-induced antidiuretic action and increase in NESR were markedly attenuated. Qualitatively similar results were observed for high-frequency RNS. In addition, high-frequency RNS-induced renal vasoconstriction was significantly suppressed by AE0047 infusion at higher doses. Lower doses of AE0047 (10 ng/kg/min) tended to attenuate the low- and high-frequency RNS-induced antidiuretic actions, although neither of the RNS-induced increases in NESR were suppressed by lower doses of AE0047. Nicardipine (50 ng/kg/min) also increased the level of basal urine formation, but the RNS-induced changes in renal function and increases in NESR were not affected by this drug. These results suggest that AE0047 suppresses the RNS-induced NE overflow from renal nerve endings, which is probably involved in the inhibitory effects of the drug on the antidiuretic action elicited by RNS.

Footnotes

  • Send reprint requests to: Yasuo Matsumura, Ph. D., Department of Pharmacology, Osaka University of Pharmaceutical Sciences 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan. E-mail:matumrh{at}oysun01.oups.ac.jp

  • Abbreviations:
    RNS
    renal nerve stimulation
    NE
    norepinephrine
    AE0047
    (±)-2-[4-(4-benzhydrylpiperazin-1-yl) phenyl] ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate dihydrochloride
    MAP
    mean arterial blood pressure
    HR
    heart rate
    RBF
    renal blood flow
    GFR
    glomerular filtration rate
    UF
    urine flow
    UNaV
    urinary excretion of sodium
    FENa
    fractional excretion of sodium
    FF
    filtration fraction
    RVR
    renal vascular resistance
    NESR
    norepinephrine secretion rate
    • Received October 4, 1999.
    • Accepted March 1, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 293 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 293, Issue 3
1 Jun 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibitory Effects of AE0047, a New Dihydropyridine Ca2+ Channel Blocker, on Renal Nerve Stimulation-Induced Renal Actions in Anesthetized Dogs
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Inhibitory Effects of AE0047, a New Dihydropyridine Ca2+ Channel Blocker, on Renal Nerve Stimulation-Induced Renal Actions in Anesthetized Dogs

Tomoyuki Yamasaki, Masaji Ohmagari, Isao Tamai, Kazutaka Hayashi and Yasuo Matsumura
Journal of Pharmacology and Experimental Therapeutics June 1, 2000, 293 (3) 1040-1047;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Inhibitory Effects of AE0047, a New Dihydropyridine Ca2+ Channel Blocker, on Renal Nerve Stimulation-Induced Renal Actions in Anesthetized Dogs

Tomoyuki Yamasaki, Masaji Ohmagari, Isao Tamai, Kazutaka Hayashi and Yasuo Matsumura
Journal of Pharmacology and Experimental Therapeutics June 1, 2000, 293 (3) 1040-1047;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • H2S Overproduction and Colonic Hypomotility in DM
  • A Novel Long-Acting GLP-2, HM15912, for Short Bowel Syndrome
  • MIP3a in Progressive Renal Injury Associated With Obesity
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics